GLP1R and obesity due to melanocortin 4 receptor deficiency: The use of agonists of GLP-1R has been demonstrated to be a good therapeutic approach against obesity and type 2 diabetes, by their ability to reach the CNS and modulate metabolic signals, converging in a common molecular mechanism.